Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2019 September;31(3) > Minerva Biotecnologica 2019 September;31(3):93-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Biotecnologica 2019 September;31(3):93-9

DOI: 10.23736/S1120-4826.19.02556-4

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message

Angelo ARMANDI 1, Silvia BONETTO 1 , Rinaldo PELLICANO 2, Gian Paolo CAVIGLIA 1, Marco ASTEGIANO 2, Giorgio M. SARACCO 1, Davide G. RIBALDONE 3

1 Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology, Molinette Hospital, Turin, Italy; 3 Department of Surgical Sciences, University of Turin, Turin, Italy



Dupilumab is a human monoclonal antibody that has recently been approved for the treatment of mild-to-severe atopic dermatitis. Dupilumab inhibits the interleukin (IL)-4/IL-13 signalling by binding specific subunits of the receptors. IL-4 is involved in the regulation of both innate and adaptive intestinal immune system, thus its possible role in the pathogenesis of inflammatory bowel disease (IBD) has been investigated. Several polymorphisms of IL-4 have been found in patients with IBD. Furthermore, the crucial role of IL-4 has been demonstrated in Th2-driven models of colitis as well as in Th1-related models of this disease. Finally, many studies have shown the increased production of IL-4 in two models of experimental colitis: the dextran sulphate sodium - related colitis and the oxazolone-related colitis. In the latter, a dual antagonist of IL-4/IL-13 has proved to ameliorate the course of the disease. In conclusion, IL-4 antagonists might play a role in the treatment of IBD, especially in ulcerative colitis, which shows a classic pattern of Th2-related disease.


KEY WORDS: Crohn disease; Inflammatory bowel disease; Interleukin-4; Interleukin-13; Colitis, ulcerative

inizio pagina